Upload
lamphuc
View
216
Download
0
Embed Size (px)
Citation preview
Baxter International Inc.
BAX_CorpBR11_3.06.indd 1 3/7/12 8:45 AM
About our Cover:
Kanyakorn Piasukho of Bangkok, Thailand, was diagnosed with
chronic nephritis in infancy and experienced acute kidney failure
in 2009. She relies on Baxter peritoneal dialysis products as she
awaits a possible kidney transplant.
BAX_CorpBR11_3.06.indd 2 3/6/12 5:02 PM
1
Baxter International Inc. innovates, develops, manufactures
and markets products for people with hemophilia, immune
disorders, infectious diseases, kidney disease, trauma, and
other chronic and acute medical conditions. The company’s
diverse portfolio is focused on treatments that save and sustain
lives. As a global, diversified healthcare company, Baxter
applies a unique combination of expertise in medical devices,
pharmaceuticals and biotechnology to research and create
products that advance patient care worldwide.
Baxter International Inc.
BAX_CorpBR11_3.06.indd 1 3/7/12 8:28 AM
2
Worldwide Presence
Thomas Polzer, research scientist at Baxter’s Orth, Austria, facility, conducts validation experiments on the company’s investigational recombinant factor IX product for patients with hemophilia B.
BAX_CorpBR11_3.06.indd 2 3/6/12 5:03 PM
3
BAX_CorpBR11_3.06.indd 3 3/6/12 5:03 PM
4
A Pioneer in Healthcare Baxter has been a healthcare leader for more than 80 years with a rich history of medical “firsts.” The company was responsible for the first commercially manufactured intravenous (IV) solutions, the first commercial kidney dialysis system, the first factor VIII concentrate to treat hemophilia and many other medical breakthroughs. More recent firsts include the first recombinant factor VIII processed with no blood-based additives and the first cell culture-derived pandemic influenza vaccine.
Life-Saving ProductsBaxter products are infused, injected or inhaled more than two billion times annually (or six million times a day), each time to treat a life-threatening acute or chronic condition. Patients with hemophilia, end-stage kidney disease, primary immune deficiency and a range of other diseases depend on Baxter products. This creates a common purpose among Baxter’s approximately 48,500 employees worldwide: to save and sustain lives.
Innovation is the driving force
behind Baxter’s success. The
company is a technology leader in
recombinant and plasma-derived
therapeutic proteins, IV and
dialysis solutions and devices,
drug delivery systems, and
other technologies.
Worldwide Presence
Ten-year-old Brenden Broyles of Denver, Colorado, a primary immunodeficiency patient, was a participant in Baxter’s clinical trial of an investigational therapy designed to provide subcutaneous infusion of immune globulin through a single injection site at volumes, intervals and rates comparable to intravenous infusion.
BAX_CorpBR11_3.06.indd 4 3/6/12 5:03 PM
5
Scientific Capabilities Innovation is the driving force behind Baxter’s success. The company is a technology leader in the research and development of recombinant and plasma-derived therapeutic proteins, IV and dialysis solutions and devices, drug packaging and delivery systems, and other technologies. Baxter’s businesses share expertise in medical plastics, biologics, sterilization and other scientific disciplines to create a range of life-saving products.
Global Scope Baxter products are sold in more than 100 countries, with approximately 60 percent of the company’s revenues coming from outside the United States. Baxter’s greatest growth opportunities are in developing and emerging markets, where many people with life-threatening conditions are under-treated. As the economies of these countries continue to develop, Baxter is poised to meet their healthcare needs.
Manufacturing StrengthBaxter’s manufacturing strength and commitment to quality are foundations of the company. With more than 50 production facilities in 27 countries, proprietary technologies, and complementary manufacturing platforms across its businesses, Baxter can produce high-quality products cost-effectively for local and regional markets, helping improve healthcare quality worldwide.
A Socially Responsible CitizenPart of being a great company is being a responsible corporate citizen. Baxter gives back to the communities it serves through environmental stewardship, employee volunteerism, corporate giving and other initiatives. Baxter has been recognized for its commitment to sustainability, the company’s long-term strategic approach to including social, economic and environmental considerations and opportunities to achieve its business objectives and contribute to a more sustainable world.
Simone von Fircks (left), research and development senior manager, and Irene Kinzl, research scientist, use state of the art imaging technology to select cells used in Baxter therapies at the company’s Orth, Austria, facility.
Children in the Campo Limpo region of São Paulo, Brazil, receive dental care and education thanks to Projeto Arrastão, a recipient of a grant from The Baxter International Foundation.
BAX_CorpBR11_3.06.indd 5 3/6/12 5:03 PM
6
Moris de Boer of Rotterdam, the Netherlands, has multifocal motor neuropathy (MMN), a chronic disease characterized by progressive weakness in the limbs. Baxter produces the only centrally licensed treatment across the European Union for MMN.
BAX_CorpBR11_3.06.indd 6 3/7/12 8:28 AM
7
BioScience
Baxter’s BioScience business develops recombinant and plasma-
based proteins to treat hemophilia and other bleeding disorders;
plasma-based therapies to treat immune deficiencies, alpha-1
antitrypsin deficiency, burns and shock, and other blood-related
conditions; products for regenerative medicine, such as proteins
used to promote hemostasis and wound-sealing in surgery; and
selected vaccines.
In 1941, Baxter introduced the first system for separating plasma
from whole blood and storing it for later use. Plasma contains a
number of proteins that serve various therapeutic purposes. The
company later became a leader in plasma fractionation – the
process of breaking down plasma into its component parts – to
produce a range of plasma-derived therapeutic proteins. In the
1990s, Baxter added recombinant technology to its capabilities,
enabling the company to produce some therapeutic proteins, such
as factor VIII for hemophilia, in cell culture rather than through
plasma fractionation. Baxter’s BioScience business continues to
advance medical science to research and develop new and better
life-saving products and therapies for patients.
BAX_CorpBR11_3.06.indd 7 3/6/12 5:04 PM
8
HemophiliaBaxter is a leading developer of clotting factors to treat hemophilia. This includes recombinant and plasma-based factor VIII – the clotting protein missing from the blood of people with hemophilia A – and therapies for people that develop inhibitors against clotting factor. Baxter also has a number of research and development programs aimed at improving the treatment of hemophilia and other bleeding disorders. These include a longer-acting (PEGylated) form of a full-length recombinant factor VIII protein, recombinant factor IX therapy for hemophilia B, a recombinant therapy for inhibitor patients and the first recombinant therapy for von Willebrand disease.
In 2011, Gilberto Jiménez Chávez of Mexico City experienced extreme bleeding during surgery to remove a brain tumor. Surgeons used a Baxter-produced hemostatic matrix to help control the bleeding.
Baxter’s BioScience business
continues to advance medical
science to develop new and
better life-saving products and
therapies for patients.
BioScience
BAX_CorpBR11_3.06.indd 8 3/6/12 5:04 PM
9
BioTherapeuticsBaxter is a leading provider of immunoglobulin therapies for patients with immune deficiencies. These plasma-derived therapies provide antibody replacement for patients whose immune systems do not produce enough antibodies to fight infection. In addition to primary immunodeficiency, the therapy also is being investigated for use in neurological conditions, such as Alzheimer’s disease. In Europe, the therapy has been approved to treat multifocal motor neuropathy, a degenerative disease that attacks the peripheral nerves, resulting in progressive limb weakness. Other products include albumin, a plasma-volume expander used to treat burns and maintain adequate fluid volume in critical care patients, and alpha1-proteinase inhibitor to treat alpha-1 antitrypsin deficiency, a respiratory condition that can result in early onset emphysema.
BioSurgeryIn recent years, Baxter has attained technological leadership in the research and development of biosurgery products – biological and chemical products used to stop bleeding and seal wounds in surgery – and technologies to facilitate hard tissue regeneration in orthobiologics and soft tissue repair used in a variety of surgical procedures. The company’s stem cell technologies are being explored for their potential to restore blood flow in patients with cardiovascular and peripheral artery disease.
VaccinesBaxter provides vaccines for meningitis C, tick-borne encephalitis, and seasonal and pandemic influenza. Baxter’s Vero cell technology, used in flu vaccine production, offers potential advantages over traditional egg-based vaccine production methods.
FDA approval of a prophylaxis indication for a Baxter recombinant factor VIII treatment for hemophilia A supports patients like Jay Brown of Baton Rouge, Louisiana, in infusing treatment to prevent bleeds in addition to infusing treatment after bleeds occur.
Bill Garten of Mission, Texas, participated in a Baxter Phase II trial that found that injections of a patient’s own CD34+ stem cells reduced chest pain and improved exercise ability in patients with severe angina due to chronic myocardial ischemia.
BAX_CorpBR11_3.06.indd 9 3/7/12 8:29 AM
10
Teeramanas Tanaekakarapong of Bangkok, Thailand, has had end-stage
kidney disease since 2007. He relies on Baxter peritoneal dialysis
products to maintain his normal day-to-day work and leisure activities.
BAX_CorpBR11_3.06.indd 10 3/6/12 5:04 PM
11
Medical Products
Baxter’s Medical Products business manufactures products used
in the delivery of fluids and drugs to patients. These include
intravenous (IV) solutions and administration sets, premixed drugs
and drug-reconstitution systems, pre-filled vials and syringes
for injectable drugs, IV nutrition products, infusion pumps, and
inhalation anesthetics. The business also is a leader in home-
based renal therapies, such as peritoneal dialysis, and offers other
products and services for people with end-stage kidney disease.
In 1931, Baxter introduced the first commercially produced IV
solutions, premixed in glass containers and shipped ready for use.
Baxter later introduced the world’s first flexible, plastic IV containers
and became the first company to partner with pharmaceutical firms
to premix their drugs in IV solutions for safe and efficient delivery
to patients. In recent years, Baxter’s expertise in medication
delivery has extended to IV nutrition products, infusion pumps
and inhalation anesthetics. In renal therapy, Baxter introduced the
first commercially built artificial kidney in 1956, making life-saving
dialysis possible for people with end-stage kidney disease, and
later helped commercialize peritoneal dialysis, the first home-based
dialysis therapy.
BAX_CorpBR11_3.06.indd 11 3/6/12 5:04 PM
12
Fluid SystemsBaxter is the world’s leading provider of commercially prepared IV solutions as well as frozen and ready-to-use premixed drugs in flexible IV containers. Baxter’s portfolio of IV solutions and premixed drugs is the broadest in the industry. The company also provides IV infusion pumps and administration sets, which control the delivery of IV fluids and drugs to patients.
Specialty PharmaceuticalsBaxter is a leading developer of products for parenteral, or IV, nutrition, which provides life-sustaining support for patients who cannot receive adequate nutrients orally or through other means. Baxter offers one of the broadest portfolios of parenteral nutrition, including solutions, container systems, admixing technologies, vitamins
and mineral formulas. The company also is a leader in anesthesia and sells the three most commonly used modern inhaled anesthetics for general anesthesia. Baxter’s Specialty Pharmaceuticals portfolio includes a short-acting, cardioselective-adrenergic blocker (beta blocker) used to control heart rate in patients who are at high risk for cardiac events during and after surgery.
RenalBaxter is also a leading developer of products for peritoneal dialysis (PD), a home-based therapy for people with end-stage kidney disease. Products include PD solutions, automated cyclers, connectivity devices and ancillary supplies. In addition, the company distributes products for hemodialysis (HD), which generally takes place in a hospital or clinic, and is developing a home HD
Until receiving a kidney transplant, Jim McFarlin of Champaign, Illinois, used automated peritoneal dialysis products from Baxter to cleanse his blood of toxins and waste normally removed by healthy kidneys.
Medical Products
BAX_CorpBR11_3.06.indd 12 3/6/12 5:04 PM
13
platform, which will provide another option for dialysis patients. Baxter also provides products for continuous renal replacement therapy, typically performed in the intensive care unit of a hospital, to treat acute renal failure.
BioPharma SolutionsBaxter advances the clinical and commercial development of innovative drug and drug formulation technologies through contract manufacturing. Products include prefilled injectable drugs in vials and syringes, lyophilized drugs, and biologics such as proteins and antibodies for biotechnology and pharmaceutical companies.
Nurse Heather Evans of Southlake Regional Health Centre in Newmarket, Ontario, Canada, administers parenteral nutrition using one of Baxter’s triple-chamber container systems.
Pharmacy technician Sophia Hohenberg uses a Baxter compounder to custom mix parenteral nutrition solutions at Children’s Mercy Hospital and Clinic in Kansas City, Missouri.
Baxter’s Medical Products
business manufactures products
used in the delivery of fluids and
drugs to patients. In recent years,
Baxter’s expertise in medication
delivery has extended to IV
nutrition products, infusion pumps
and inhalation anesthetics.
BAX_CorpBR11_3.06.indd 13 3/6/12 5:05 PM
14
48,500C O R P O R A T E H E A D Q U A R T E R S
Deerfield, Illinois, USA
APPROXIMATELY
1931employeesworldwide
Est
ablis
hed
2011SALES$13.89 billion
Baxter Facts in Brief
Businesses: BioScience, Medical Products
BAXTER PRODUCTS ARE USED IN:
Hospitals / Surgery centers and other outpatient clinics / Kidney dialysis centers / Doctors’ offices / Nursing homes / Rehabilitation centers / Clinical and medical research laboratories / At home under physician supervision /
2011Sales by Region
(millions)
$1,685
$5,709
$4,392
$2,107
United States
Latin Americaand Canada
Asia-Pacific
Europe
BAX_CorpBR11_3.06.indd 14 3/7/12 8:29 AM
15
MANUFACTURING
Baxter manufactures products in 27 countries:
Australia
Austria
Belgium
Brazil
Canada
Chile
China
Colombia
Costa Rica
Czech Republic
Germany
India
Ireland
Italy
Japan
Malta
Mexico
Philippines
Poland
Saudi Arabia
Singapore
Spain
Switzerland
Tunisia
Turkey
United Kingdom
United States, including Puerto Rico
RESEARCH AND DEVELOPMENT
Research and development (R&D) is essential to
Baxter’s growth. These activities are performed at
R&D centers around the world, including facilities in
Austria, Belgium, Japan and the United States, as
well as in conjunction with select R&D partners.
2011 R&D Investment: $946 million
SustainabilityBaxter has been recognized by many sustainability-related
organizations. In 2011, Baxter was named:
• totheDowJonesSustainabilityIndexforthe13thstraightyear,
and the Medical Products leader for the 10th time
• oneoftheGlobal100MostSustainableCorporationsbyCorporate
Knights Inc.
• toFortunemagazine’slistoftheWorld’sMostAdmiredCompanies
• fourthoverallinNewsweekmagazine’s“GreenRankings”ofthe500
largest U.S. companies, and first globally in the healthcare category
• tothe100BestCorporateCitizenslistbyCorporateResponsibilitymagazineBaxter is a registered trademark of Baxter International Inc.
OperationsBaxter has operations (including offices and manufacturing/
distribution facilities) in 62 countries. The company
conducts business in more than 100 countries.
BAX_CorpBR11_3.06.indd 15 3/6/12 5:05 PM
16
1939First sterile blood-collection container
1956First commercially built artificial kidney
1968First commercially produced factor VIII concentrate to treat hemophilia
1978First ambulatory dialysis system
1979First automated blood-cell separator
1982First heat-treated factor VIII, reducing risk of viral transmission
1998First triple-chamber container system for parenteral nutrition
1941First plasma-collection and storage unit
1959First flexible, plastic blood-collection system
1988First factor VIII purified by chemical and monoclonal techniques
1991First needle-less system for IV therapy
1992First recombinant factor VIII
2007First needle-less IV connector with an antimicrobial coating
2011First triple-chamber container system for parenteral nutrition designed specifically for pediatric patients
1971First flexible, plastic IV container
2003First recombinant factor VIII made without any added human or animal proteins
2005First albumin in a flexible, plastic container
2009First cell culture-based pandemic influenza vaccine
1974First premixed IV drugs
1977First therapy for people with hemophilia who develop antibodies against clotting factor
Baxter History of Firsts
1931First commercially manufactured IV solutions
BAX_CorpBR11_3.06.indd 16 3/6/12 5:05 PM
Des
ign:
par
agra
phs.
com
© Baxter International Inc., 2012. All rights reserved. References in this report to Baxter are intended to refer collectively to Baxter International Inc. and its U.S. and international subsidiaries.
BAX_CorpBR11_3.06.indd 17 3/6/12 5:05 PM
Baxter International Inc.One Baxter ParkwayDeerfield, Illinois 60015-4625USA
www.baxter.com
Regional Headquarters Locations
Europe, Middle East and AfricaBaxter Healthcare SAP.O. BoxCH-8010 ZürichSwitzerland
Asia PacificBaxter (China) Investment Co. Ltd.10F Platinum Tower233 Tai Cang RoadShanghai, 200020China
Latin America/CanadaBaxter Export Corporation101 Northeast 3rd Avenue, Suite 1600Fort Lauderdale, FL 33301-1181USA
Printed on recycled paper containing 10% post-consumer recovered fiber using soy-based inks.
BAX_CorpBR11_3.06.indd 18 3/6/12 5:05 PM